Data completeness
1/8 — Limited
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TACE is an oral small-molecule capsule in pre-launch development by Sanofi under NDA review. The mechanism of action, indication(s), and therapeutic class are not yet disclosed in public sources. Patient eligibility and clinical positioning will be clarified upon regulatory approval and market entry.
Pre-Launch
As a pre-launch asset, TACE represents a growth opportunity; commercial team size and market entry timing remain dependent on regulatory approval and competitor landscape.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
Started Mar 2026
40 enrolled
HCC - Hepatocellular Carcinoma
TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk
Started Mar 2026
105 enrolled
Hepato Cellular Carcinoma (HCC)
Deep Learning-Based Multidimensional Body Composition Mapping for Outcome Prediction in HCC Patients Undergoing TACE
Started Nov 2025
300 enrolled
Hepatocellular Carcinoma
TACE Treats Nodular Goiter
Started Sep 2025
30 enrolled
Nodular Goiter
Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
Started Apr 2025
24 enrolled
Hepatocellular Carcinoma (HCC)Unresectable Hepatocellular Carcinoma
Worked on TACE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.